A. Keith Stewart, MB, ChB

Professor, Carlson and Nelson Endowed Director, Center for Individualized , Vasek and Anna Maria Polak Professor of Cancer Research

  • 19733 Citations
  • 77 h-Index
1988 …2020
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 21 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Dexamethasone Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Thalidomide Medicine & Life Sciences
Genes Medicine & Life Sciences
Survival Medicine & Life Sciences
Proteasome Inhibitors Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2007 2020

Multiple Myeloma
Oncolytic Virotherapy
Clonal Evolution
Vesicular Stomatitis
Research

The Role of Cereblon Pathways in Myeloma

Stewart, A. K. & Kumar, S. K.

National Institutes of Health

4/1/143/31/19

Project: Research project

Drug Resistance
Thalidomide
Multiple Myeloma
Pharmaceutical Preparations
Mutation
Cyclin-Dependent Kinase 5
Multiple Myeloma
Proteasome Inhibitors
RNA Interference
Vesicle-Associated Membrane Protein 2
RNA Interference
Genome
Cell Line
Pharmaceutical Preparations
Thalidomide

Research Output 1988 2019

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

Zhu, Y. X., Shi, C. X., Bruins, L. A., Wang, X., Riggs, D. L., Porter, B., Ahmann, J. M., de Campos, C. B., Braggio, E. D., Bergsagel, P. L. & Stewart, A. K., Feb 1 2019, In : Blood cancer journal. 9, 2, 19.

Research output: Contribution to journalArticle

Open Access
Multiple Myeloma
Cell Line
Down-Regulation
lenalidomide
Sequence Deletion

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M., Stewart, A. K., Hari, P., Roy, V., Vescio, R., Kaufman, J. L., Berg, D., Liao, E., Rajkumar, S. V. & Richardson, P. G., Jan 1 2019, In : Leukemia.

Research output: Contribution to journalArticle

Multiple Myeloma
Dexamethasone
Maintenance
Stem Cell Transplantation
Disease-Free Survival

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S. & 1 othersBerdeja, J. G., Feb 1 2019, In : Blood cancer journal. 9, 2, 17.

Research output: Contribution to journalArticle

Open Access
Multiple Myeloma
Anti-Idiotypic Antibodies
Maximum Tolerated Dose
Antibodies
Pharmaceutical Preparations
7 Citations (Scopus)

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., Samur, M., Towfic, F., Ortiz, M., Flynt, E., Yu, Z., Yang, Z., Rozelle, D., Obenauer, J., Trotter, M., Auclair, D. & 19 othersKeats, J., Bolli, N., Fulciniti, M., Szalat, R., Moreau, P., Durie, B., Stewart, A. K., Goldschmidt, H., Raab, M. S., Einsele, H., Sonneveld, P., San Miguel, J., Lonial, S., Jackson, G. H., Anderson, K. C., Avet-Loiseau, H., Munshi, N., Thakurta, A. & Morgan, G., Jul 2 2018, (Accepted/In press) In : Leukemia. p. 1-12 12 p.

Research output: Contribution to journalArticle

Disease-Free Survival
Multiple Myeloma
Survival
Genome
Exome
2 Citations (Scopus)
Paraproteinemias
Multiple Myeloma
Precision Medicine
Genetic Predisposition to Disease
Cytogenetics